MMMahdieh Mondanizadeh

Mahdieh Mondanizadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mahdieh Mondanizadeh has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Valproic acid enhances temozolomide efficacy via epigenetic Upregulation of miR-124-3p and Suppression of Sp1 in glioma

    by Elyar Mahboubi, Mehdi Sadegh, Behzad Khansarinejad, Mahdieh Mondanizadeh, Mohammad Hasan Sakhaie

  • Open Access

    Diagnostic Significance of microRNA-146 in Asthma: A Systematic Review

    by Zahra Shojaei, Behzad Khansarinejad, Amir Almasi-Hashiani, Mahdieh Mondanizadeh, Javad Nazari

  • Open Access

    Harmine-loaded PCL/PVA multilayer nanofibers for targeted pancreatic cancer therapy

    by Zeynab Zamanzadeh, Behzad Khansarinejad, Mahdieh Mondanizadeh, Shima Masodii, Hadi Karami

  • Antisense oligonucleotides: targeting oncogenic long non-coding RNAs for cancer therapy

    by Hamed Irandoost, Mahdieh Mondanizadeh, Elahe Irandoost

    This narrative review aims to summarize current evidence on antisense oligonucleotide (ASO)-based strategies targeting oncogenic long non-coding RNAs (lncRNAs) and to evaluate their therapeutic potential in cancer initiation, progression, metastasis, and treatment resistance. A narrative review of preclinical studies was conducted, focusing on ASO-mediated silencing of cancer-associated lncRNAs, including MALAT1, PVT1, NEAT1, and other emerging lncRNAs, across multiple malignancies such as lung, breast, ovarian, gastrointestinal, and head-and-neck cancers. Advances in ASO chemical design and delivery strategies-including lipid and polymeric nanoparticles, ligand-directed conjugates, peptide-based carriers, and gymnotic uptake-were also examined. Preclinical evidence consistently demonstrates that lncRNA-targeted ASOs effectively suppress tumor growth, invasion, metastasis, and chemoresistance while promoting apoptosis. Improvements in ASO chemical modifications and delivery platforms have significantly enhanced ASO stability, biodistribution, and intracellular uptake, thereby improving therapeutic efficacy across diverse cancer models. Targeting oncogenic lncRNAs using ASO-based approaches represents a promising and rapidly evolving strategy in precision oncology. Although substantial progress has been achieved in ASO design and delivery, further optimization and well-structured clinical trials are required to facilitate the translation of these therapies into routine cancer treatment.


  • Silent Signals: The Expanding Role of Cell-Free DNA in Women’s Health, Pregnancy, and Reproductive Medicine

    by Matin Dolatabadi, Mahdieh Mondanizadeh

    Cell-free DNA (cfDNA) is an emerging biomarker detectable in various bodily fluids, with promising implications across a wide range of clinical domains. Its minimally invasive nature, short half-life, and ability to reflect tissue-specific genetic and epigenetic alterations position cfDNA as a key tool in women’s health diagnostics. This narrative review aims to explore the biological characteristics, release mechanisms, and clinical utility of cfDNA in gynecological cancers, pregnancy-related disorders, and assisted reproductive technologies (ART), highlighting current applications, benefits, limitations, and future perspectives. A comprehensive literature review was conducted using databases including PubMed, Scopus, Web of Science, and Google Scholar. Relevant peer-reviewed articles from January 2005 to March 2025 were analyzed to summarize advances in cfDNA detection techniques, clinical applications, and emerging technologies in women’s health. In gynecology, cfDNA—especially circulating tumor DNA—has shown promise in early cancer detection, mutation analysis, and disease monitoring. In prenatal medicine, fetal cfDNA (cffDNA) in maternal plasma enables highly accurate, noninvasive screening for chromosomal abnormalities and pregnancy complications such as preeclampsia and intrauterine growth restriction. In reproductive medicine, cfDNA derived from follicular fluid and embryo culture media may serve as a novel biomarker for assessing oocyte and embryo quality. cffDNA offers a noninvasive method for fetal genetic evaluation in pregnancy loss cases, enabling the detection of chromosomal abnormalities to inform clinical management. Technological innovations such as fragmentomics, methylation analysis, and artificial intelligence are enhancing the analytical power and clinical relevance of cfDNA. cfDNA offers a transformative, noninvasive approach for improving diagnosis, prognosis, and personalized care in women’s health. While clinical implementation still faces technical and standardization challenges, emerging tools and multi-omics integration are expected to strengthen the role of cfDNA in precision medicine. Future large-scale studies and validation across diverse populations are essential to support its routine clinical adoption.

  • Open Access

    Psychological resilience as a mediator in infertile women: A structural equation modeling analysis of self-efficacy, stigma, and fertility quality of life

    by Anahid Behbahani Mondanizadeh, Rezvan Homaei, Fariba Hafezi, Marzieh Talebzadeh Shoushtari

    Background: Infertility poses significant psychosocial challenges for women, profoundly impacting their well-being and quality of life. Infertility stigma and self-efficacy, reflecting a woman's confidence in managing infertility-related challenges, are key factors influencing this experience. Objectives: This study examined the mediating role of psychological resilience in the associations between infertility stigma, infertility self-efficacy, and fertility-related quality of life (FertiQoL) among infertile women. Methods: A cross-sectional, correlational design was employed, involving 295 infertile women recruited via convenience sampling from fertility clinics in Ahvaz, Iran, in 2024. Data were collected using the Fertility Quality of Life (FertiQoL) scale, Infertility Stigma Scale (ISS), Infertility Self-Efficacy Scale (ISES), and Connor-Davidson Resilience Scale (CD-RISC). Structural Equation Modeling (SEM) was conducted using SPSS and AMOS software to analyze relationships. Results: The model demonstrated a strong fit to the data. Direct paths from infertility stigma and selfefficacy to FertiQoL were non-significant. However, significant direct associations were found between infertility stigma and resilience (β=-0.22, P<0.001), and between self-efficacy and resilience (β=0.24, P<0.001). Psychological resilience significantly mediated the relationships between infertility stigma and FertiQoL (β=-0.06, P=0.001), and between self-efficacy and FertiQoL (β=0.01, P=0.001), indicating its critical role in these pathways. The final structural model exhibited good fit to the data (χ²/df=1.60, CFI=0.94, RMSEA=0.04). Conclusion: Psychological resilience serves as a vital protective factor, mitigating the adverse effects of infertility stigma and enhancing the positive influence of self-efficacy on FertiQoL. These findings underscore the importance of fostering resilience in clinical interventions to improve psychological wellbeing and quality of life among infertile women. Implications for Nursing and Midwifery Preventive Care  Psychological resilience plays a pivotal role in enhancing FertiQoL among infertile women.  Nursing interventions should prioritize resilience-building strategies, such as cognitivebehavioral therapy and mindfulness, to alleviate infertility stigma.  Targeted support to enhance self-efficacy further strengthens resilience and emotional well-being.  Resilience-focused holistic care empowers women to effectively navigate infertility challenges.

  • Open Access

    Exploring the effects of doxorubicin on survival rates in glioma patients: a comprehensive systematic review

    by Elyar Mahboubi, Mahdieh Mondanizadeh, Amir Almasi-Hashiani, Elham Ghasemi

    Background: Glioma is still one of the most aggressive and common types of brain and central nervous system cancer, with few effective treatment options. Despite progress in therapy, there is a requirement for new methods to enhance patient outcomes. Doxorubicin (DOX), a type of anthracycline that has been proven to be effective in different cancers, encounters difficulties in treating glioma because of the blood–brain barrier. This systematic review is intended to assess the effects of DOX on the survival and quality of life of glioma patients. Methods: We conducted a thorough search and found 1576 records, from which 10 studies met our inclusion criteria. These studies, published between 1973 and 2023, were examined for overall survival (OS), progression-free survival (PFS), median time to progression (mTTP), response rate, and toxicity profiles. Results: The studies included in the analysis showed that OS ranged from 6 to 18.5 months, indicating potential improved outcomes with liposomal and PEGylated forms of DOX. PFS rates varied from 15 to 58%, and mTTP ranged from 11 to 39.83 weeks. Response rates varied from 19 to 88%, and while DOX was generally well-tolerated, some hematological and non-hematological toxicities were observed. DOX shows promise in prolonging survival and slowing glioma progression, especially with advanced delivery methods. Conclusions: However, variations in research, small sample sizes, and lack of uniformity highlight the need for further investigation. Overcoming these limitations in future studies is crucial to maximize DOX's effectiveness in glioma treatment and improve patient outcomes.


  • Correlation of miRNA-124-3p and SP1 expression levels in spinal cord injury

    by Maryam Zand, Mehdi Sadegh, Behzad Khansarinejad, Mahdieh Mondanizadeh


  • Open Access

    MicroRNA-124-3p and Brain-derived Neurotrophic Factor in Rat Spinal Cord Injury: Inverse Expression Pattern

    by Maryam Zand, Mehdi Sadegh, Behzad Khansarinejad, Mahdieh Mondanizadeh

    Spinal cord injury (SCI) significantly impacts the central nervous system, with limited effective treatments available. Brain-derived neurotrophic factor (BDNF) plays a crucial role in neuronal growth, survival, and regeneration after SCI. MicroRNAs, particularly miR-124-3p, have been implicated in SCI pathophysiology. However, the relationship between miR-124-3p and BDNF in the context of SCI remains unclear. This study aimed to investigate the correlation between miR-124-3p expression and BDNF levels in a rat model of spinal cord injury and to assess how the timing of injury affects this relationship.


  • Open Access

    Quantification of the Most Effective X-Ray Dosage for Inhibiting Invasion of Glioma Cell Line

    by Elham Ghasemi, Zeynab Zamanzade, Fatemeh Seif, Mahdieh Mondanizadeh

    Background: One key feature that distinguishes cancerous cell populations from their normal counterparts is a heightened tendency towards uncontrolled growth and invasive activity. Therapeutic techniques like radiotherapy can impact the viability and invasive behavior of cancer cells by modifying the structure of DNA and inducing programmed cell death. Methods: This research is an experimental study and involved a comprehensive investigation into the effects of 6MV X-ray radiotherapy on various absorbed doses (ranging from 4 to 10 Gy by steps 2Gy) on toxicity, migration, and colony formation in C6 glioblastoma cellular cultures. Results: Our detailed analysis revealed that the cytotoxic responses increased in a dose-dependent manner, while there was a significant decrease in both the ability to migrate and form colonies in the C6 cell line. Conclusions: This thorough examination provides new insights into the way malignant cell populations respond to ionizing radiation in a dose-dependent manner within a clinical setting. By directly impacting cellular functions and causing disturbances, this occurrence leads to a slowing down of disease progression.